HemoSonics

About HemoSonics

HemoSonics, a medical device company established in 2004, operates at the intersection of diagnostics and acute care, focusing on the management of critical bleeding. The company was founded by Bill Walker and Dr. Francesco Viola, whose background in biomedical engineering and ultrasound technology laid the groundwork for the firm's core technology. Dr. Viola's graduate work at the University of Virginia, which centered on ultrasound imaging and signal processing, directly inspired the development of the company's proprietary technology. Based in Durham, North Carolina, HemoSonics has been part of the Stago Group since its acquisition on May 30, 2017.

The company's business revolves around its flagship product, the Quantra Hemostasis Analyzer. This system is sold to hospitals for use in point-of-care settings like operating rooms, intensive care units, and emergency departments. Revenue is generated from the sale of the analyzer and the associated single-use disposable cartridges, the QPlus and QStat. The business model targets a critical need in acute medical situations: providing fast, actionable data to guide transfusion decisions, thereby improving patient outcomes and managing the use of blood products efficiently.

The Quantra Hemostasis Analyzer is a point-of-care diagnostic system that provides a comprehensive assessment of a patient's blood coagulation status in under 15 minutes. A key feature is its proprietary SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry technology, which uses medical-grade ultrasound to measure the viscoelastic properties of a whole blood sample as it clots. This technology provides clinicians with clear, graphical results on parameters like clot time and stiffness, enabling them to quickly identify the cause of bleeding and make informed decisions about which blood products are needed. The system has received multiple FDA clearances, including De Novo authorization in March 2019 for the Quantra Analyzer and QPlus cartridge. Subsequent clearances have expanded its indications to include trauma, liver transplantation, major orthopedic surgery, and cardiovascular surgery, as well as the use of both venous and arterial blood samples.